The invention relates to the use of ferroportin inhibitor compounds of the general formula (I)
The invention relates to the use of ferroportin inhibitor compounds of the general formula (I)
for treating myelodysplastic syndromes (MDS).
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Recorded and downloadable media, computer software, blank
digital or analogue recording and storage media for use in
the medical and pharmaceutical field; downloadable mobile
applications for the management and transmission of
information in the medical and pharmaceutical field;
downloadable publications in the medical and pharmaceutical
field; electronic publications in the medical and
pharmaceutical field. Medical apparatus and instruments; Surgical apparatus and
instruments for medical use; implantable medical devices;
apparatus for use in medical analysis. Printed publications and printed educational publications in
the medical and pharmaceutical field. Advertising; Marketing and promotion services; services in
this class related to the manufacture, marketing and
distribution of pharmaceutical products and medical products
and supplies; retail and wholesale services including retail
and wholesale services for pharmaceutical products and
medical products and supplies, veterinary and sanitary
products and medical supplies; design of promotional
material; marketing advisory services; planning of marketing
strategies; preparation of marketing plans; provision of
information relating to advertising, marketing, and
promotion services in the pharmaceutical industry; provision
of information relating to wholesale and retail services in
the pharmaceutical industry; provision of information
relating to promotion services in the field of promoting
awareness of nephrological and iron deficiency anaemia
diseases, and promoting awareness of pharmaceutical and
health treatments. Providing access to a digital platform to facilitate and
assist healthcare professionals and patient to interact with
each other and with third parties; Providing access to
platforms and portals on the Internet. Medical training services; Conducting of educational
seminars and training relating to medical and pharmaceutical
matters; publication of journals, newspapers, catalogues,
leaflets, brochures, magazines, manuals, booklets, posters,
and texts relating to the medical and pharmaceutical field;
publication of photographs relating to the medical and
pharmaceutical field; providing non-downloadable videos
relating to the medical and pharmaceutical field. Providing scientific information in the field of medical
disorders and their treatment; Provision of information and
data relating to medical and pharmaceutical research and
development; providing medical and scientific research
information relating to diseases, pharmaceuticals, and
clinical trials; hosting websites on the Internet; providing
a webhosting platform to facilitate and assist healthcare
professionals and patients to interact with each other and
with third parties; software as a service (SaaS) featuring
software for analyzing and reporting self-assessment of
illness; software as a service (SaaS) featuring software
platforms for use in providing medical and scientific
research information to pharmaceutical companies, health
care providers, healthcare professionals, and patients. Medical information; Health care information services;
medical diagnostic services; providing information in the
field of administering medication. Providing personal support services for patients and
families of patients with nephrological and iron deficiency
anaemia diseases, namely, emotional counseling and emotional
support.
The present invention relates to novel synthesis methods of methyl 2-fluoroacrylate (MFA) which is a key precursor for the production of Veltassa® (Patiromer). The methods according to the invention are conducted by reacting an α-substituted β-hydroxy propionic acid derivative (I) via one or more intermediate steps involving one or more α-, β-substituted propionic acid derivatives (II) to obtain MFA (III).
C07C 67/317 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groupsPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenolysis of functional groups
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
41 - Education, entertainment, sporting and cultural services
Goods & Services
Chemicals for use in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; fire extinguishing and fire prevention compositions; tempering and soldering preparations; substances for tanning animal skins and hides; adhesives for use in industry; putties and other paste fillers; compost, manures, fertilizers; biological preparations for use in industry and science. Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Education; providing of training; entertainment; sporting and cultural activities; providing online and offline information and educational materials in the field of health education and educational support programs for patients; organizing and conducting online and in-person seminars and training sessions to inform and guide patients regarding diseases, treatment options, and therapy management.
5.
FERROPORTIN-INHIBITORS FOR THE USE IN THE TREATMENT OF HEREDITARY HAEMOCHROMATOSIS (HH)
The invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates, hydrates or polymorphs thereof for the use in the treatment of hereditary hemochromatosis.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 39/00 - General protective or antinoxious agents
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Recorded and downloadable media, computer software, blank digital or analogue recording and storage media for use in the medical and pharmaceutical field; downloadable mobile applications for the management and transmission of information in the medical and pharmaceutical field; downloadable publications in the medical and pharmaceutical field; electronic publications in the medical and pharmaceutical field. Medical apparatus and instruments; Surgical apparatus and instruments for medical use; implantable medical devices; apparatus for use in medical analysis. Printed publications and printed educational publications in the medical and pharmaceutical field. Advertising; marketing and promotion services; business management and administrative services related to the manufacture, marketing and distribution of pharmaceutical products and medical products and supplies; retail and wholesale services including retail and wholesale services for pharmaceutical products and medical products and supplies, veterinary and sanitary preparations and medical supplies; design of marketing material; marketing advisory services; planning of marketing strategies; preparation of marketing plans; provision of information relating to advertising, marketing, and promotion services in the pharmaceutical industry; provision of information relating to wholesale and retail services in the pharmaceutical industry; provision of information relating to promotion services in the field of promoting awareness of nephrological and iron deficiency anaemia diseases, and promoting awareness of pharmaceutical and health treatments. Providing access to a digital platform to facilitate and assist healthcare professionals and patient to interact with each other and with third parties; providing access to platforms and portals on the Internet. Medical education services; conducting of educational seminars and training relating to medical and pharmaceutical matters; publication of journals, newspapers, photographs, catalogues, leaflets, brochures, magazines, manuals, booklets, posters, and texts relating to the medical and pharmaceutical field; providing non-downloadable videos relating to the medical and pharmaceutical field. Providing scientific information in the field of medical disorders and their treatment; provision of information and data relating to medical and pharmaceutical research and development; Providing medical and scientific research information relating to diseases, pharmaceuticals, and clinical trials; hosting websites on the Internet; software as a service [SaaS] featuring software for analyzing and reporting self-assessment of illness; software as a service [SaaS] featuring software platforms for use in providing medical and scientific research information to pharmaceutical companies, health care providers, healthcare professionals, and patients. Medical information services; health care information services; medical diagnostic services; patient support services. Providing personal support services for patients and families of patients with nephrological and iron deficiency anaemia diseases, namely, emotional counseling and emotional support.
The invention relates to novel compounds of the general formula (1-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and/or iron overload.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
8.
CALCIUM OXALATE CRYSTALLIZATION INHIBITORS FOR RENAL DISORDERS
The present invention relates to inositol derivatives comprising two or more cyclohexanolpentakisester moieties linked by a common central linker and their use in therapy or prevention of a condition related to pathological crystallization. The invention further relates to useful intermediates in the synthesis of the compound of the invention.
A61K 31/80 - Polymers containing hetero atoms not provided for in groups
C07C 43/196 - Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
C08G 65/34 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
The invention relates to novel compounds of the general formula (I), which are characterized in that at least one of the groups A and B contains at least 3 rings, pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and/or iron overload.
The invention relates to novel compounds of the general formula (I), which are characterized in that at least one of the groups A and B contains at least 3 rings, pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and/or iron overload.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and/or iron overload.
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
11.
Clinical Dosing Schedule of Inositol Phosphate Oligo(Ethylene Glycol) Compounds
The invention relates to a dosing schedule for an inositol polyphosphate oligo(ethylene glycol) compound, or its pharmaceutically acceptable salt used in the treatment or prevention of a disease associated with formation of, and/or tissue exposure to, calcium salt crystals. The drug compound is administered at an interval of one week.
The invention is related to an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
40 - Treatment of materials; recycling, air and water treatment,
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical and biological reagents, included in this class;
cell cultures and media, included in this class; laboratory
and scientific test kits, included in this class; chemical
preparations for scientific and industrial use; diagnostic
agents and testing means; chemical and biological reagents
for non-medical use; chemical and biological reagents for
industrial use for anti-body screening, blood grouping, and
for the typing and detection of specific blood cells,
determining the presence of antigens on blood cells, and the
detection of relevant complement compounds and
immunoglobulin subtypes; chemical test kits for the
detection of specific blood cells, determining the presence
of antigens on blood cells, and the detection of relevant
complement compounds and immunoglobulin subtypes for
laboratory or research purposes; chemical preparations for
industrial use for anti-body screening, blood grouping, and
the typing and detection of specific blood cells. Bleaching preparations and other substances for laundry use;
cleaning, polishing, degreasing and abrasive preparations;
soaps; perfumery, essential oils, cosmetics, hair lotions;
dentifrices. Pharmaceutical preparations and substances; blood plasma;
blood products, included in this class; products derived
from blood and products derived from recombinant DNA
technology; vaccines; serums for medical use; antibodies;
monoclonal antibodies; reagent red-blood cells; test kits,
included in this class; diagnostic products, included in
this class; blood products; medical and veterinary test
kits; influenza vaccines; adjuvants and antigens;
pharmaceutical preparations and substances for the treatment
and prevention of blood or bleeding disorders; blood
products, namely, blood plasma, reagent blood cells;
products derived from blood and products derived from
recombinant DNA technology, namely, immunoglobulins, human
albumin, blood clotting factors, plasma volume expanders,
blood proteins for therapeutic use; serums for medical use,
namely, antivenom; medicated serums for the treatment of
blood or bleeding disorders; test kits, namely, in-vitro
diagnostic reagent test kits for use in detecting
cell-mediated immune response; pharmaceutical preparations
and substances, namely, rhesus factor-D reagents for the
detection of specific antigens or in blood typing;
pharmaceutical preparations, namely, reagent red blood cells
used to detect antibodies or immunoglobulin G subtypes;
pharmaceutical preparations, namely, monoclonal and
polyclonal antibodies; pharmaceutical preparations, namely,
reagents for medical or clinical use for the typing and
detection of specific blood cells, and the detection of
relevant complement components and immunoglobulin subtypes;
pharmaceutical or veterinary preparations for use in
oncology and diabetes; pharmaceutical or veterinary
preparations for use in transplantation, transplantation
rejection therapy and transplantation-associated diseases
and conditions; pharmaceutical or veterinary preparations
comprising stem cells; pharmaceutical or veterinary
preparations for use in dialysis-associated diseases,
conditions and complications; pharmaceutical or veterinary
preparations for use in preserving or improving renal
function, for the treatment or prevention of acute kidney
injury, for the treatment or prevention of chronic kidney
diseases and associated complications; pharmaceutical or
veterinary preparations for the treatment or prevention of
cardiac, cardiovascular, circulatory, renal system, kidney,
cardio-renal, immune system, gastroenterological,
gastrointestinal, stomach, dermatological, hematological,
bone, respiratory, genetic, allergic, inflammation,
infectious, pain, central nervous system, endocrinology,
hormonal, muscular, rheumatic, ocular and metabolic diseases
and disorders; pharmaceutical and veterinary preparations
used as immune system stimulators; pharmaceutical
preparations for the treatment or prevention of mineral
deficiencies or mineral overload as well as diseases and
conditions associated with mineral deficiencies or mineral
overload; pharmaceutical preparations for the treatment or
prevention of metal deficiencies or metal overload as well
as diseases and conditions associated with metal
deficiencies or metal overload; pharmaceutical preparations
for the treatment or prevention of vitamin deficiencies or
vitamin overload as well as diseases and conditions
associated with vitamin deficiencies or vitamin overload,
vitamin and mineral supplements, vitamin preparations and
mineral preparations for medical use; sanitary products for
medical purposes; dietetic foods for medical or veterinary
use; food for babies; food supplements for humans and
animals; medical plasters, medical dressings; material for
dental fillings and dental impressions; disinfectants. Software; application software; downloadable software
applications; computer software and programs; electronic or
recorded multimedia publications; publications in electronic
form; electronic audiovisual teaching materials; printed
publications in electronically readable or downloadable
form; electronic publications provided on line, from the
internet or from any other communication network;
educational materials in the form of computer software and
programs, including applications for use on mobile
telephones; educational materials in the form of
pre-recorded media including discs, DVDs, compact discs,
flash drives; software that can represent goods virtually;
downloadable digital files authenticated by non-fungible
tokens [NFTs]. Surgical and medical apparatus and instruments; implantable
medical devices; analysis apparatus and instruments for
medical use, included in this class; medical apparatus and
instruments, included in this class; test kits, included in
this class. Printed matter and publications; instructional or teaching
material (except apparatus); brochures, pamphlets, flyers,
posters. Advertising; marketing and promotional services; marketing
of pharmaceutical products and medical products and
supplies; retail and wholesale services including retail and
wholesale services for pharmaceutical products and medical
products and supplies, veterinary preparations and sanitary
products and medical supplies; marketing advisory services;
planning of marketing strategies; preparation of marketing
plans; provision of information relating to advertising,
marketing, and promotion services; provision of information
relating to wholesale and retail services; marketing through
product placement in online games or in virtual
environments; preparation of statistics. Treatment of waste materials; treatment of biological
products including custom manufacturing and fractionation of
blood to the order and requirements of a customer; treatment
and transformation of reagents and ancillary products for
immunohaematology laboratories for third parties to order;
processing of human blood plasma, namely, removing whole
blood and separating red blood cells from plasma; treatment
of human blood and plasma; fractionation of human blood and
plasma; custom manufacturing of human blood and plasma to
the order and requirements of a customer. Education services including medical training services;
health training; consultancy services relating to
training/education; provision of education services via an
online forum; provision of training and education courses;
publication of educational material; dissemination of
educational material; entertainment via weblog (blog)
services; electronic publication of information on a wide
range of topics, including online and over a global computer
network; entertainment services, namely online provision of
non-downloadable virtual goods for use in virtual
environments; providing online electronic publications, not
downloadable. Scientific and technological services; research and
development services, including scientific, medical,
pharmaceutical and blood product research and development
services; industrial analysis services; clinical trials;
clinical research; provision of testing facilities; rental
of research facilities; laboratory analysis and research;
technical planning of scientific research projects;
preparation of technical studies, technical reports,
scientific reports; conducting of scientific and medical
research projects, preparation of reports relating to
scientific and medical research; provision of research
services and facilities, provision of research results,
information and outcomes; provision of information relating
to all the aforementioned services; consultancy services
relating to all the aforementioned services; provision of
information relating to the aforementioned services over a
global computer network; medical research laboratory
services, namely, scientific studies and testing of human
blood plasma for safety and quality (screening); medical
research laboratory services regarding human blood plasma
for medical diagnostics; design of marketing material;
hosting of blogs. Medical services; medical information services; health care
services; health care information services; medical
diagnostic services (testing and analysis); patient support
services; medical, pharmaceutical and blood product
consultancy services; medical advisory services; information
services concerning pharmaceuticals, medical products and
blood products; dissemination of information regarding the
aforementioned services over a global computer network;
blood bank services; operating blood and plasma collection
centres; medical testing and screening services; medical
testing of human blood plasma; collection, processing and
testing of human blood and plasma; providing medical
information concerning blood products; providing medical
information concerning vaccines, antivenoms and
immunohaematology products, namely, diagnostic reagents;
patient support services, namely, providing patient medical
information where patients can enquire about medical issues
and procedures from other patients and can relay information
about their medical experiences for support and community
creation purposes via an Internet-based database.
15.
Process for the Production of Ferroportin Inhibitors
The invention relates to a new process for preparing compounds of the formula (I)
The invention relates to a new process for preparing compounds of the formula (I)
The invention relates to a new process for preparing compounds of the formula (I)
and pharmaceutically acceptable salts thereof, which act as ferroportin inhibitors being suitable for the use as medicaments in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or of iron metabolism disorders leading to increased iron levels or increased iron absorption, including iron overload, thalassemia, sickle cell disease and hemochromatosis.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The invention relates to novel compounds of the general formula (l-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and/or iron overload.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 25/00 - Drugs for disorders of the nervous system
Injectable iron compositions comprising iron, a carbohydrate, a stabilizing agent and water are provided. These iron compositions can be prepared by mixing iron with a carbohydrate and water to form a mixture and adding a stabilizing agent to the mixture to form the stable injectable iron composition. These compositions can be considered “ready-to-use” and can treat a variety of diseases, disorders, or conditions characterized by iron deficiency or dysfunctional iron metabolism, for example, anemia.
A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
The invention relates to novel compounds of the general formula (I), which are characterized in that at least one of the groups A and B contains at least 3 rings, pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and/or iron overload.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
22.
Ferroportin-Inhibitors For The Use In The Prevention And Treatment Of Kidney Injuries
The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for preventing and treating kidney injuries, such as in particular acute kidney injuries, and the symptoms and pathological conditions associated therewith.
The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for preventing and treating kidney injuries, such as in particular acute kidney injuries, and the symptoms and pathological conditions associated therewith.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
23.
Methods And Compositions For Treating Sickle Cell Disease With A Ferroportin Inhibitor (VIT-2763)
The invention relates to compounds of the formula
The invention relates to compounds of the formula
The invention relates to compounds of the formula
and pharmaceutically acceptable salts thereof for the use in the treatment of sickle cell disease and for the use in preventing and treating vascular inflammation and vaso-occlusion.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
24.
Ferroportin-Inhibitors For The Use In The Treatment Of Transfusion-Dependent Beta-Thalassemia (TDT)
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The invention relates to intravenously administered ferric carboxymaltose for the use as a diuretic medicament, in particular for the treatment of congestion, or of congestion associated with impaired function of the heart and/or associated with deterioration of the function of the heart in a patient suffering from heart failure with iron deficiency or in a patient being iron deficient and at risk of developing heart failure.
The present invention relates to inositol derivatives comprising two or more cyclohexanolpentakisester moieties linked by a common central linker and their use in therapy or prevention of a condition related to pathological crystallization. The invention further relates to useful intermediates in the synthesis of the compound of the invention.
The invention relates to a new process for preparing compounds of the formula (I) and pharmaceutically acceptable salts thereof, which act as ferroportin inhibitors being suitable for the use as medicaments in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or of iron metabolism disorders leading to increased iron levels or increased iron absorption, including iron overload, thalassemia, sickle cell disease and hemochromatosis.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
The invention relates to particles of a mixture of iron(l I l)-oxyhydroxide, sucrose and one or more starches, preferably of sucroferric oxyhydroxide having a certain particle size distribution, a process for the manufacture thereof, the pharmaceutical composition comprising the same, in particular compressed tablets.
The invention relates to novel compounds of the general formula (I),
with Het-2 being an optionally substituted bicyclic heteroaryl of the formula
pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof for the use in the treatment of sickle cell disease and for the use in preventing and treating vascular inflammation and vaso-occlusion.
The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for preventing and treating kidney injuries, such as in particular acute kidney injuries, and the symptoms and pathological conditions associated therewith.
The invention relates to novel compounds of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as iron chelators, more particularly for the use in the prophylaxis and/or treatment of diseases related to or caused by excess or increased iron levels, increased iron absorption or iron overload in a mammal, such as in particular thalassemia, hemochromatosis and ineffective erythropoiesis, or related to or caused by blood transfusions.
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
The invention relates to intravenously administered ferric carboxymaltose for the use as a diuretic medicament, in particular for the treatment of congestion, or of congestion associated with impaired function of the heart and/or associated with deterioration of the function of the heart in a patient suffering from heart failure with iron deficiency or in a patient being iron deficient and at risk of developing heart failure.
The invention relates to novel salts of compounds of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia, sickle cell disease and hemochromatosis.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The invention relates to novel compounds of the general formula (I),
with Het-2 being an optionally substituted bicyclic heteroaryl of the formula
pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention relates to novel salts of compounds of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia, sickle cell disease and hemochromatosis.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 25/00 - Drugs for disorders of the nervous system
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Bleaching preparations and other substances for laundry use;
cleaning, polishing, degreasing and abrasive preparations;
soaps; perfumery, essential oils, cosmetics, hair lotions;
dentifrices. Pharmaceutical products, medical and veterinary
preparations; sanitary products for medical purposes;
dietetic food and substances for medical or veterinary use,
food for babies; food supplements for humans and animals;
plasters, materials for dressings; material for dental
fillings and dental impressions; disinfectants. Education; training; entertainment; sporting and cultural
activities. Scientific and technological services as well as research
and design relating thereto; industrial analysis and
research services; design and development of computers and
software. Medical services; veterinary services; hygienic and beauty
care for human beings or animals.
45.
Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.
The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Education; providing of training; entertainment; sporting
and cultural activities. Scientific and technological services and research and
design relating thereto; industrial analysis and research
services; design and development of computers and software. Medical and veterinary services; hygienic and beauty care
for human beings or animals.
48.
Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention
of hyperkalemia; pharmaceutical preparations for the
treatment and prevention of renal, cardiovascular,
gastrointestinal and endocrine diseases or disorders;
pharmaceutical preparations for reducing potassium levels;
non-absorbed pharmaceutical preparations, namely,
pharmaceutical preparations for the treatment and prevention
of hyperkalemia and renal, cardiovascular, gastrointestinal,
and endocrine disorders; polymeric pharmaceutical
preparations, namely, pharmaceutical preparations for the
treatment and prevention of hyperkalemia and renal,
cardiovascular, gastrointestinal, and endocrine disorders.
The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.
The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Education; training; entertainment; sporting and cultural
activities. Medical assistance; veterinary assistance; hygienic and
beauty care for human beings and animals; agriculture,
horticulture and forestry services.
53.
FE(III) COMPLEXES FOR TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANAEMIAS
The invention relates to iron(III) complexes and to pharmaceutical compositions comprising them for use as a medicament, especially for treatment and/or for prophylaxis of iron deficiency symptoms and iron deficiency anaemias.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Education, namely, providing educational information in the field of iron deficiency to healthcare professionals; providing health related educational information in the field of iron deficiency
(2) Medical assistance, namely providing medical advice in the field of iron deficiency
55.
FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIA
The invention relates to iron(III)-2-oxo-butane diamide complex compounds and pharmaceutical compositions comprising same for use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemia.
The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Education; training; entertainment; sporting and cultural
activities. Scientific and technological services and research and
design relating thereto; industrial analysis and research
services; design and development of computers and software. Medical assistance; veterinary assistance; hygienic and
beauty care for human beings or animals.
59.
Receptacle and method for storing and supplying a liquid and a liquid medical preparation
A method and a receptacle for storing and supplying a liquid, especially a liquid medical preparation. It is an object of the invention to provide a suitable receptacle and method for storing and supplying a desired liquid quantity. It is solved by a liquid tight and preferably gas-tight receptacle, comprising a compressible tube (7) or foil bag. A rigid opening portion (6) is sealingly mounted to one end of the tube (7). The diameter of the opening portion (6) is the same as the diameter of the tube (7). The tube (7) diameter is not more than 10 mm The liquid has a volume of not more than 1.5 ml, preferably of not more than 1.3 ml. The tube (7) contains additionally a gas having a volume of 10 to 15% of the liquid volume. The tube (7) or foil bag comprises a flat portion having an inscription.
B65D 85/00 - Containers, packaging elements or packages, specially adapted for particular articles or materials
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
The invention relates to iron(III) complex compounds and to pharmaceutical compositions containing the same for use as medicinal products, particularly for the treatment and/or prophylaxis of iron-deficiency phenomena and iron-deficiency anaemia.
The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.
The invention relates to iron(III) 2,4-dioxo-1-carbonyl complexes and to pharmaceutical compositions comprising them for use in the treatment for prophylaxis of iron deficiency symptoms and iron deficiency anaemias.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary products as well as
preparations for health care, including parapharmaceutical
products; dietetic products for medical use, food for
babies; plasters, materials for dressings; material for
dental fillings and dental impressions; disinfectants.
64.
FE(III) COMPLEXES FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANAEMIAS
The invention relates to iron(III) complexes and pharmaceutical compositions in which they are present for use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anaemias.
The present invention relates to novel hepcidin antagonists of formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anaemias, in particular anaemias in connection with chronic inflammatory diseases (ACD: anaemia of chronic disease and Al; anaemia of inflammation).
A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
C07D 215/40 - Nitrogen atoms attached in position 8
The present invention relates to iron carbohydrate complex compounds, wherein the carbohydrate is selected from the group which consists of natural carbohydrates or synthetic carbohydrate derivatives, such as starch, hydrolyzed starches, dextrins (In particular maltodextrin, maltose syrup, glucose syrup, cyclodextrins), dextrin derivatives (in particular oxidized dextrins, especially oxidized maltodextrins or hydrogenated dextrins), and pullulan and derivatives thereof, for the use in the intravenous therapy of malaria patients.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary products as well as health
care preparations, including parapharmaceutical products;
dietetic products for medical use, food for babies;
plasters, materials for dressings; material for dental
fillings and dental impressions; disinfectants.
The invention relates to a tip cap assembly for closing a distal opening of a receptacle like a syringe body or a tube in a sealed manner, and to a method for producing the tip cap. A cap assembly according to the invention comprises a frangible tip of a receptacle, preferably a pre-filled receptacle. An upper portion of the tip closes the receptacle respectively a lower tip portion comprising a passage as known from the state of the art. Hence, the receptacle is reliably sealed to prevent contamination or loss of the medication. Compared with the state of the art, a receptacle has a more effectively sealed tip. It is necessary to break the upper tip portion away in order to open the receptacle. A cap element protects the tip on one side. On the other side, unscrewing the cap breaks the upper portion away without hurting a person.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary products as well as healthcare
preparations, except cardio-vascular preparations for
treating hypertension and metabolic disorders unrelated to
iron deficiency.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations as well as
preparations for health care, excluding cardio-vascular
preparations for treating hypertension and metabolism
disorders that are unrelated to iron deficiency.
72.
FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS
The invention relates to iron(III) complex compounds and pharmaceutical compounds comprising same for use as medicaments, in particular for the treatment and/or for the prophylaxis of iron deficiency symptoms and iron deficiency anemias.
05 - Pharmaceutical, veterinary and sanitary products
30 - Basic staples, tea, coffee, baked goods and confectionery
Goods & Services
(1) Pharmaceutical iron preparations for the treatment of iron deficiency and anaemia due to iron deficiency, for human use; pharmaceutical vitamin preparations for human use, namely Beta-Carotin, Biotin, Folic acid, reduced Folate derivatives, Pantothenic acid, Vitamin A, B1 to B12, C, D active vitamin D preparations, E, K
The present invention relates to novel hepcidine antagonists of the general structural formula, pharmaceutical compositions comprising the same, and the use thereof as medications, particularly for treating iron metabolism disorders, such as in particular iron deficiency diseases and anemias, in particular anemias in conjunction with chronic inflammatory diseases (ACD, anemia of chronic disease, and AI, anemia of inflammation).
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
The present invention relates to novel hepcidine antagonists of the formula (I), comprising pharmaceutical compositions and the use thereof as medications, in particular for treating iron metabolism disorders, such as in particular iron deficiency diseases and anemias, in particular anemias in conjunction with chronic inflammatory diseases (ACD, anemia of chronic disease, and AI, anemia of inflammation).
C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
C07D 251/18 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
C07D 251/66 - Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
The invention relates to novel hepcidin antagonists of formula (I), to pharmaceutical compositions containing same, and to the use thereof as a medicament, especially for treating iron metabolism disorders such as especially iron deficiency diseases and anaemia, especially anaemia related to chronic inflammation diseases (ACD; anaemia of chronic disease and AI; anaemia of inflammation).
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
C07D 307/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
The present invention relates to novel hepcidin antagonists of the general formula (I), to pharmaceutical compositions comprising them and to the use thereof as medicaments, especially for treatment of iron metabolism disorders, such as especially iron deficiency disorders and anemias, especially anemias in conjunction with chronic inflammatory disorders (ACD; anemia of chronic disease and AI; anemia of inflammation).
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
The invention relates to novel hepcidine antagonists of formula (I), pharmaceutical compositions comprising the same, and to the use thereof as medicaments, in particular for treating iron metabolism disorders, for example, iron deficiency diseases and anaemias, in particular anaemias combined with chronic inflammation diseases (ACD; anemia of chronic disease and AI; anemia of inflammation).
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
79.
Water-soluble iron carbohydrate derivative complexes, the preparation thereof, and medicaments comprising them
Water-soluble iron-carbohydrate derivative complex obtainable from an aqueous iron(III) salt solution and an aqueous solution of the product of the oxidation and subsequent derivative of one or more maltodextrins with an aqueous hypochlorite solution at an alkaline pH value, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of each individual maltodextrin in the mixture is from 2 to 40, and the subsequent derivative is carried out with a suitable reagent, process for the preparation thereof, and medicament for the treatment and prophylaxis of iron deficiency states.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
The present invention relates to a dialysis machine for the purification of blood, a manifold for the dialysis machine as well as to a process for the regeneration of the dialysis bath. It is an object of the present invention to provide a dialysis machine, a manifold for the dialysis machine as well a process which facilitates the administration of medical preparations during a dialysis procedure. In order to solve the object, a dialysis machine according to the present invention comprises tubes (1, 5, 8) connected with a dialyzer (6), means for delivering pharmaceuticals into the tubes and a pump (11) for the transport of blood through the tubes and the dialyzer. The dialysis machine comprises means for administration (4) of at least one pharmaceutical by a suction effect of the pump or by a pressure effect of the pump or by an excess 15 pressure of a gas or a liquid.
The present invention relates to a dialysis machine for the purification of blood, a manifold for the dialysis machine as well as to a process for the regeneration of the dialysis bath. It is an object of the present invention to provide a dialysis machine, a manifold for the dialysis machine as well a process which facilitates the administration of medical preparations during a dialysis procedure. In order to solve the object, a dialysis machine according to the present invention comprises tubes (1, 5, 8) connected with a dialyzer (6), means for delivering pharmaceuticals into the tubes and a pump (11) for the transport of blood through the tubes and the dialyzer. The dialysis machine comprises means for administration (4) of at least one pharmaceutical by a suction effect of the pump or by a pressure effect of the pump or by an excess pressure of a gas or a liquid.
Subject of the present invention are compositions comprising a mixture of calcium, magnesium and iron salts for use as a pharmaceutical preparation for adsorbing phosphate, especially for use as pharmaceutical preparations for the treatment of hyperphosphataemia, chronic kidney deficiency as well as for the treatment of haemodialysis patients.
The invention relates to a tip cap assembly for closing a distal opening of a receptacle like a syringe body or a tube in a sealed manner, and to a method for producing the tip cap. A cap assembly according to the invention comprises a frangible tip of a receptacle, preferably a pre-filled receptacle. An upper portion of the tip closes the receptacle respectively a lower tip portion comprising a passage as known from the state of the art. Hence, the receptacle is reliably sealed to prevent contamination or loss of the medication. Compared with the state of the art, a receptacle has a more effectively sealed tip. It is necessary to break the upper tip portion away in order to open the receptacle. A cap element protects the tip on one side. On the other side, unscrewing the cap breaks the upper portion away without hurting a person.
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A61M 39/20 - Closure caps or plugs for connectors or open ends of tubes
84.
RECEPTACLE AND METHOD FOR STORING AND SUPPLYING A LIQUID AND A LIQUID MEDICAL PREPARATION
A method and a receptacle for storing and supplying a liquid, especially a liquid medical preparation. It is an object of the invention to provide a suitable receptacle and method for storing and supplying a desired liquid quantity. It is solved by a liquid tight and preferably gas-tight receptacle, comprising a compressible tube (7) or foil bag. A rigid opening portion (6) is sealingly mounted to one end of the tube (7). The diameter of the opening portion (6) is the same as the diameter of the tube (7). The tube (7) diameter is not more than 10 mm. The liquid has a volume of not more than 1.5 ml, preferably of not more than 1.3 ml. The tube (7) contains additionally a gas having a volume of 10 to 15 % of the liquid volume. The tube (7) or foil bag comprises a flat portion having an inscription.
The invention provides an iron-carbohydrate complex compound which is characterized by a content of iron(II). The invention also provides processes for the preparation of the iron-carbohydrate complex compound and the use thereof for treatment of iron deficiency anaemias.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
A dispensing device for the sporadic dispensing of tablets of a tablet stack is proposed. A delivery element (200), which can be moved back and forth relative to the housing between a dispensing position and a delivery position, is arranged in a housing (100). The dispensing device further comprises holding means, in particular a lift element (300), which act to hold the tablet stack stationary relative to the housing during a movement of the delivery element from the dispensing position into the delivery position and take the stack along in the direction of the removal opening when the delivery element returns to the dispensing position. In this way the tablet stack is advanced in the delivery direction during a back and forth movement of the delivery element by a predetermined distance, in particular by the thickness of a single tablet, and the individual tablet can easily be removed.
B65D 83/04 - Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, spherical or like small articles, e.g. tablets or pills
Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
Water-soluble iron-carbohydrate derivative complex obtainable from an aqueous iron(III) salt solution and an aqueous solution of the product of the oxidation and subsequent derivatization of one or more maltodextrins with an aqueous hypochlorite solution at alkaline pH, wherein, in the case of use of a maltodextrin whose dextrose equivalent is from 5 to 20 and in the case of use of a mixture of a plurality of maltodextrins, the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of each individual maltodextrin involved in the mixture is from 2 to 40, and the subsequent derivatization is effected with a suitable reagent, processes for preparing them and medicaments for treatment and prophylaxis of iron deficiency conditions.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
39 - Transport, packaging, storage and travel services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Soaps, perfumery, essential oils, cosmetics, hair lotions;
dentifrices. Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes, including
parapharmaceutical products; dietetic substances adapted for
medical use, food for babies; plasters, materials for
dressings; material for stopping teeth, dental wax;
disinfectants. Services of an import agency, especially relating to
medicines and pharmaceutical preparations; retail business
services with goods; services of an import-export agency,
especially relating to medicines, pharmaceutical and
sanitary preparations. Services in the field of transport and warehousing of goods,
especially transport, storage and delivery as well as
packaging of goods, especially of medicines, pharmaceutical
and sanitary preparations. Providing of training, especially in the pharmacy and
sanitary field. Research, development of medicines, pharmaceutical
preparations and sanitary care products. Legal services and representation of third parties to the
authorities and administration, especially for the admission
of medicines.
The present invention relates to a container (1, 1′, 1″) for the intake and release of a medicament, in particular a parenteral medicament, the container (1, 1′, 1″) exhibiting a casing (6, 6′) which is sealed, except for an opening (7) for the purpose of releasing the medicament, the container (1, 1′, 1″) being designed in such a way that a release of the medicament is effected by alteration of at least one region of the casing (6, 6′). The casing (6, 6′) is furthermore formed in one piece. The container exhibits a hollow needle (9, 10).
A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
The invention relates to an iron-hydrocarbon complex compound which is characterized by an iron (II) content. The invention also relates to methods for producing said iron-hydrocarbon complex compound as well as the use thereof for the treatment of iron deficiency anemia.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
94.
MULTICOMPARTMENT BAG FOR STORAGE OF IRON PREPARATIONS
The present invention relates to multicompartment bags, for storage, in particular long-term storage, of iron preparations, in particular high-dose iron preparations, which are intended for parenteral administration to a patient in need of such iron preparations.
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Education; training; entertainment; sporting and cultural
activities. Scientific and technological services and related research
and design services; industrial analysis and research
services; design and development of computers and software;
legal services.
